Our path at NewBridge is defined by three strategic imperatives:


  1. Be the partner-of-choice and licensee for research-based pharmaceutics, biologics and genomic companies seeking to market their FDA and EMA/European approved products in the MENA Region; and providing them with a ”one-stop” and complete regional solution.
  2. Be the preferred partner for existing pharmaceutical companies in the region who solicit the services of NewBridge to further their brand equity and maintain their presence in the region.
  3. Introduce NewBridge’s own propriety brands complementary to our core business model and our existing portfolio.